What chemotherapy regimen would you recommend to a patient with local regional recurrent ER negative, HER2 positive breast cancer who received TCH more than 5 years ago?   

The CALOR trial included patients that could receive HER2-targeted therapy.



Answer from: Medical Oncologist at Academic Institution